Literature DB >> 18222546

Effect of time of preparation on pentagastrin-induced symptom, endocrine and cardiovascular responses.

Samir Khan1, Hedieh Briggs, James Lawrence Abelson.   

Abstract

Pentagastrin is a cholecystokinin (CCK)-B agonist and laboratory panicogenic agent that produces endocrine (ACTH and cortisol), symptom (anxiety, panic) and cardiovascular (heart rate) responses. Although in vitro data have supported its chemical stability, preliminary data suggested that increasing time between drug preparation and drug infusion could reduce the magnitude of endocrine and symptom responses. The current study examined this possibility. Twenty-one healthy subjects presented at the University of Michigan General Clinical Research Center (GCRC) and had an intravenous catheter inserted. Heart rate, cortisol levels and subjective anxiety were measured before and after pentagastrin and placebo injections. Pentagastrin was prepared either within 60 min of IV infusion (Normal Preparation group) or at least 3.5 h prior to infusion (Early Preparation group). Relative to the Normal Preparation group, Early Preparation subjects had similar heart rate responses but significantly smaller cortisol and subjective anxiety responses. Early preparation of pentagastrin thus appears to weaken endocrine and subjective anxiety responses, highlighting the importance of attending to often overlooked procedural variables (e.g., time between preparation and administration) in studies of this type. The sensitivity of cortisol and anxiety responses to preparation time, but insensitivity of heart rate, is consistent with previous studies suggesting different thresholds of activation for the three response modalities. These differential sensitivities may suggest different and separable CCK-B stimulated pathways for each response, which combine to produce panic, rather than a single, unified CCK-B mediated panicogenic response.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18222546      PMCID: PMC2290743          DOI: 10.1016/j.psychres.2007.10.020

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  14 in total

1.  Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers.

Authors:  D Koszycki; R M Zacharko; J M Le Mellédo; J Bradwejn
Journal:  Depress Anxiety       Date:  1998       Impact factor: 6.505

Review 2.  Cholecystokinin and panic disorder: past and future clinical research strategies.

Authors:  J Bradwejn; D Koszycki
Journal:  Scand J Clin Lab Invest Suppl       Date:  2001

3.  Cognitive modulation of the endocrine stress response to a pharmacological challenge in normal and panic disorder subjects.

Authors:  James L Abelson; Israel Liberzon; Elizabeth A Young; Samir Khan
Journal:  Arch Gen Psychiatry       Date:  2005-06

Review 4.  Increased anxiogenic effects of caffeine in panic disorders.

Authors:  D S Charney; G R Heninger; P I Jatlow
Journal:  Arch Gen Psychiatry       Date:  1985-03

5.  Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder.

Authors:  J Bradwejn; D Koszycki; G Meterissian
Journal:  Can J Psychiatry       Date:  1990-02       Impact factor: 4.356

6.  Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses.

Authors:  J L Abelson; R M Nesse
Journal:  Biol Psychiatry       Date:  1994-07-15       Impact factor: 13.382

7.  Effect of repeat exposure on neuroendocrine and symptom responses to pentagastrin.

Authors:  Samir Khan; Israel Liberzon; James L Abelson
Journal:  Psychiatry Res       Date:  2004-05-30       Impact factor: 3.222

8.  Effects of propranolol on symptom and endocrine responses to pentagastrin.

Authors:  Samir Khan; Israel Liberzon; James L Abelson
Journal:  Psychoneuroendocrinology       Date:  2004-10       Impact factor: 4.905

Review 9.  Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models.

Authors:  Susan Rotzinger; Franco J Vaccarino
Journal:  J Psychiatry Neurosci       Date:  2003-05       Impact factor: 6.186

10.  Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers.

Authors:  Peter Zwanzger; Daniela Eser; Frank Padberg; Thomas C Baghai; Cornelius Schule; Florian Rötzer; Robin Ella; Hans-Jürgen Möller; Rainer Rupprecht
Journal:  Depress Anxiety       Date:  2003       Impact factor: 6.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.